Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy

[1] Turner JJ(2010)InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions Blood 116 e90-e98

[2] Morton LM(2013)Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 381 1817-1826

[3] Linet MS(2013)Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes Int J Cancer 132 2659-2666

[4] Clarke CA(2007)Altered immunity as a risk factor for non-Hodgkin lymphoma Cancer Epidemiol Biomarkers Prev 16 405-408

[5] Kadin ME(2012)T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting J Hematol Oncol 5 A3-1024

[6] Vajdic CM(2010)AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model Leukemia 24 1018-239

[7] Monnereau A(2012)Activation-induced cytidine deaminase in B cell immunity and cancers Immune Netw 12 230-2214

[8] Maynadié M(2012)Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients Cancer Immunol Immunother 61 2207-290

[9] Chiu BC(2014)Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas Nat Med 20 283-1388

[10] Marcos-Gragera R(2013)At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity Eur J Immunol 43 1383-57

[1] Turner JJ(2010)InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions Blood 116 e90-e98

[2] Morton LM(2013)Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 381 1817-1826

[3] Linet MS(2013)Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes Int J Cancer 132 2659-2666

[4] Clarke CA(2007)Altered immunity as a risk factor for non-Hodgkin lymphoma Cancer Epidemiol Biomarkers Prev 16 405-408

[5] Kadin ME(2012)T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting J Hematol Oncol 5 A3-1024

[6] Vajdic CM(2010)AID-induced T-lymphoma or B-leukemia/lymphoma in a mouse BMT model Leukemia 24 1018-239

[7] Monnereau A(2012)Activation-induced cytidine deaminase in B cell immunity and cancers Immune Netw 12 230-2214

[8] Maynadié M(2012)Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients Cancer Immunol Immunother 61 2207-290

[9] Chiu BC(2014)Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas Nat Med 20 283-1388

[10] Marcos-Gragera R(2013)At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity Eur J Immunol 43 1383-57